<DOC>
	<DOCNO>NCT00806923</DOCNO>
	<brief_summary>This 3 arm study evaluate efficacy safety add Avastin versus placebo standard chemotherapeutic regimen patient advanced recurrent non-squamous non-small cell lung cancer ( NSCLC ) receive prior chemotherapy . The anticipated time study treatment disease progression , target sample size 500+ individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Patients With Non-Squamous Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; document inoperable , locally advanced , metastatic recurrent nonsquamous NSCLC ; adequate liver kidney function ; woman childbearing potential must negative serum pregnancy test within 7 day start study treatment . prior chemotherapy treatment another systemic cancer therapy ; surgery ( include open biopsy ) , significant traumatic injury , radiotherapy within last 4 week prior first dose study treatment ; brain metastasis spinal cord compression ; fertile men , woman childbearing potential , use adequate contraception ; treatment investigational agent , participation another clinical trial , within 30 day prior enter study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>